EP3731837A4 - The combination comprising linagliptin and metformin - Google Patents

The combination comprising linagliptin and metformin Download PDF

Info

Publication number
EP3731837A4
EP3731837A4 EP18913688.0A EP18913688A EP3731837A4 EP 3731837 A4 EP3731837 A4 EP 3731837A4 EP 18913688 A EP18913688 A EP 18913688A EP 3731837 A4 EP3731837 A4 EP 3731837A4
Authority
EP
European Patent Office
Prior art keywords
linagliptin
metformin
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP18913688.0A
Other languages
German (de)
French (fr)
Other versions
EP3731837A2 (en
Inventor
Ali TÜRKYILMAZ
Nur PEHLIVAN AKALIN
Merve ERGUN DONMEZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanovel Ilac Sanayi ve Ticaret AS
Original Assignee
Sanovel Ilac Sanayi ve Ticaret AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanovel Ilac Sanayi ve Ticaret AS filed Critical Sanovel Ilac Sanayi ve Ticaret AS
Publication of EP3731837A2 publication Critical patent/EP3731837A2/en
Publication of EP3731837A4 publication Critical patent/EP3731837A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
EP18913688.0A 2017-12-25 2018-12-21 The combination comprising linagliptin and metformin Pending EP3731837A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2017/21505A TR201721505A2 (en) 2017-12-25 2017-12-25 The combination comprising linagliptin and metformin
PCT/TR2018/050857 WO2019194773A2 (en) 2017-12-25 2018-12-21 The combination comprising linagliptin and metformin

Publications (2)

Publication Number Publication Date
EP3731837A2 EP3731837A2 (en) 2020-11-04
EP3731837A4 true EP3731837A4 (en) 2021-06-30

Family

ID=67900634

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18913688.0A Pending EP3731837A4 (en) 2017-12-25 2018-12-21 The combination comprising linagliptin and metformin

Country Status (3)

Country Link
EP (1) EP3731837A4 (en)
TR (1) TR201721505A2 (en)
WO (1) WO2019194773A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022173406A1 (en) * 2021-02-15 2022-08-18 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi A process for formulations of linagliptin or a pharmaceutically acceptable salt thereof
CN117858703A (en) * 2021-07-22 2024-04-09 新梅斯托克公司 Method for preparing pharmaceutical composition comprising linagliptin and metformin hydrochloride
WO2023075826A1 (en) * 2021-10-28 2023-05-04 The Texas A&M University System Compositions of stable metformin and similar drug products with control on nitroso impurities
WO2023163510A1 (en) * 2022-02-23 2023-08-31 주식회사 제뉴원사이언스 Pharmaceutical complex formulation with controlled drug release comprising linagliptin or pharmaceutically acceptable salt thereof and metformin or pharmaceutically acceptable salt thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2848242A1 (en) * 2013-09-12 2015-03-18 Sanovel Ilac Sanayi ve Ticaret A.S. Orally disintegrating formulations of Linagliptin
WO2015107536A2 (en) * 2013-12-09 2015-07-23 Intas Pharmaceuticals Limited Fixed dose combination comprising linagliptin and metformin hci

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012031124A2 (en) 2010-09-03 2012-03-08 Bristol-Myers Squibb Company Drug formulations using water soluble antioxidants
WO2014080383A1 (en) 2012-11-26 2014-05-30 Ranbaxy Laboratories Limited Pharmaceutical composition of dipeptidyl peptidase-iv (dpp-iv) inhibitors in combination with other antidiabetics
WO2015110962A1 (en) 2014-01-21 2015-07-30 Wockhardt Limited Solid oral pharmaceutical compositions comprising fixed dose combination of metformin and linagliptin or salts thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2848242A1 (en) * 2013-09-12 2015-03-18 Sanovel Ilac Sanayi ve Ticaret A.S. Orally disintegrating formulations of Linagliptin
WO2015107536A2 (en) * 2013-12-09 2015-07-23 Intas Pharmaceuticals Limited Fixed dose combination comprising linagliptin and metformin hci

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2019194773A2 *

Also Published As

Publication number Publication date
WO2019194773A3 (en) 2019-12-12
TR201721505A2 (en) 2019-07-22
WO2019194773A2 (en) 2019-10-10
EP3731837A2 (en) 2020-11-04

Similar Documents

Publication Publication Date Title
EP3508580A4 (en) Novel promoter and use thereof
IL278171A (en) Gip derivatives and uses thereof
EP3665303A4 (en) Clec9a binding agents and use thereof
EP3889249A4 (en) Exosome and various uses thereof
EP3453401A4 (en) Interleukin combination and use thereof
EP3611233A4 (en) Ink and ink set
EP3689936A4 (en) Blocked polyisocyanate composition and use thereof
EP3731837A4 (en) The combination comprising linagliptin and metformin
EP3733849A4 (en) Improved promoter and use thereof
IL267184A (en) Phenylamidines and the use thereof as fungicides
EP3802613A4 (en) Dimer and use thereof
SG11201908281VA (en) Phenalene-1-one-containing photosensitizer composition, phenalene-1-one compound and the use thereof
IL277502A (en) Compounds and uses thereof
SG11202008543RA (en) Pyrrolidineamide derivatives and uses thereof
IL279483A (en) Cyanotriazole compounds and uses thereof
EP3901146A4 (en) Phenylpyrrolidine compound and use thereof
IL267258A (en) Phenoxyphenylamidines and the use thereof as fungicides
EP3766696A4 (en) Laminate and use thereof
EP3713465A4 (en) The pedestool
IL280369A (en) New myokines and uses thereof
EP3744358A4 (en) Tissue-joining member, and use thereof
EP3694519A4 (en) The pharmaceutical combination comprising dapoxetine and phosphodiesterase type-5
EP3703805A4 (en) Magnetically-assisted delivery into and through the skin
EP3634475A4 (en) Reducing the toxicity ofagrobacterium
EP3694707A4 (en) Phosphonates and uses thereof

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200718

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20210601

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/155 20060101AFI20210526BHEP

Ipc: A61K 31/522 20060101ALI20210526BHEP

Ipc: A61K 9/20 20060101ALI20210526BHEP

Ipc: A61P 3/10 20060101ALI20210526BHEP

Ipc: A61K 9/48 20060101ALI20210526BHEP

Ipc: A61K 47/22 20060101ALI20210526BHEP

Ipc: A61K 47/32 20060101ALI20210526BHEP

TPAC Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOSNTIPA

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230708

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20231222